Study Summary
This trial will study the effects of nebulized furosemide on pulmonary inflammation in patients with COVID-19 who are intubated and on mechanical ventilation.
Eligible Conditions
- Coronavirus
- Respiratory Failure
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 6 Secondary · Reporting Duration: Day 60 post enrollment
Baseline to day 28
Requirement for mechanical ventilation
Day 60 post enrollment
Mortality
Study Day 6
Improvement in pulmonary gas exchange
Day 28
Requirement for supplemental oxygen
Day 60
Adverse events
Duration of ICU Stay
Length of hospitalization
Up to day 28
Cytokine levels
Electrolyte abnormalities
Inhalation adverse events
Serum levels of furosemide
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
2 Treatment Groups
Inhaled Furosemide
1 of 2
Nebulized Saline
1 of 2
Experimental Treatment
Non-Treatment Group
640 Total Participants · 2 Treatment Groups
Primary Treatment: Nebulized Furosemide · Has Placebo Group · Phase 2 & 3
Inhaled Furosemide
Drug
Experimental Group · 1 Intervention: Nebulized Furosemide · Intervention Types: DrugNebulized Saline
Drug
PlaceboComparator Group · 1 Intervention: Nebulized Saline · Intervention Types: DrugTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 60 post enrollment
Who is running the clinical trial?
University Health Network, TorontoOTHER
1,382 Previous Clinical Trials
472,835 Total Patients Enrolled
Queen's UniversityLead Sponsor
336 Previous Clinical Trials
110,308 Total Patients Enrolled
John Muscedere, MDPrincipal InvestigatorQueens University
2 Previous Clinical Trials
2,020 Total Patients Enrolled
Eligibility Criteria
Age 18 - 100 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:References
- Brennecke, Anja, Laura Villar, Zhiyu Wang, Lisa M. Doyle, Autumn Meek, Mark Reed, Christopher Barden, and Donald F. Weaver. 2020. “Is Inhaled Furosemide a Potential Therapeutic for COVID-19?”. The American Journal of the Medical Sciences. Elsevier BV. doi:10.1016/j.amjms.2020.05.044.
- Wang, Zhiyu, Yanfei Wang, Prachi Vilekar, Seung-Pil Yang, Mayuri Gupta, Myong In Oh, Autumn Meek, et al.. 2020. “Small Molecule Therapeutics for COVID-19: Repurposing of Inhaled Furosemide”. Peerj. PeerJ. doi:10.7717/peerj.9533.
- Brennecke A, Villar L, Wang Z, Doyle LM, Meek A, Reed M, Barden C, Weaver DF. Is Inhaled Furosemide a Potential Therapeutic for COVID-19? Am J Med Sci. 2020 Sep;360(3):216-221. doi: 10.1016/j.amjms.2020.05.044. Epub 2020 Jun 1.
- Dr. John Muscedere 2021. "Furosemide as Supportive Therapy for COVID-19 Respiratory Failure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04588792.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments